CVT/Astellas To Submit Regadenoson In Mid-2007, Following Successful Phase III Studies
Selective adenosine receptor agonist could replace market leader Adenoscan as the myocardial perfusion imaging agent of choice, CVT says.
Selective adenosine receptor agonist could replace market leader Adenoscan as the myocardial perfusion imaging agent of choice, CVT says.